Phase 1 Study of RP-6306 With Carboplatin and Paclitaxel in TP53 Ovarian and Uterine Cancer

Metastatic Cancer Clinical Trial

— GyneRep  

Official title:

Phase I Study of the PKMYT1 Inhibitor RP-6306 in Combination With Carboplatin and Paclitaxel for the Treatment of Recurrent TP53 Ovarian and Uterine Cancer

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT06107868
• Other study ID #: OZUHN-019
• Secondary ID: CAPCR 23-5475
• Status: Active, not recruiting
• Phase: Phase 1
• Start date: March 20, 2024
• Est. completion date: December 4, 2026

Study information

• Verified date: March 2024
• Source: University Health Network, Toronto
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase 1 study to evaluate investigational drug RP-6306 in combination with carboplatin and paclitaxel in patients with TP53 mutated ovarian or uterine cancer. The dose escalation part of the study will determine the maximum tolerated dose (MTD) and recommended Phase 2 Dose (RP2D) and schedule of RP-6306 in combination with carboplatin and paclitaxel and the dose expansion will further assess the safety and tolerability as well as determine the preliminary efficacy of RP-6306 in combination with carboplatin and paclitaxel.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 24
• Est. completion date: December 4, 2026
• Est. primary completion date: December 4, 2026
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Written informed consent

• Females =18 years old at the time of signature of the consent form.

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 28 days prior to enrollment.

• All patients must have histologically proven, locally advanced or metastatic recurrent ovarian and uterine cancer. Patients will be eligible only if available curative therapy does not exist.

• Ovarian and uterine cancer should be high-grade and TP53 abnormal by immunohistochemistry or TP53 mutated by genomic profiling.

• Patients must be eligible for re-challenge carboplatin and paclitaxel.

• Patient must have archival tissue available for molecular profiling.

• Measurable disease as per Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 at the time of enrollment.

• Ability to comply with the protocol and study procedures.

• Acceptable study required organ function at screening

• Acceptable study required hematologic function at screening

• Negative pregnancy test (serum) for women of child-bearing potential (WOCBP) at screening. WOCBP who are sexually active and their partners must agree to use a highly effective form of contraception throughout their participation during the study and for 6 months after the last dose of study treatment.

• Resolution of all toxicities of prior therapy or surgical procedures to baseline or Grade 1 (except for neuropathy, hypothyroidism requiring medication, and alopecia, which must have resolved to Grade =2).

• Any prior radiation must have been completed at least 7 days prior to the start of study treatment, and patients must have recovered from any acute adverse effects prior to the start of study treatment.

• Life expectancy =12 weeks after the start of the treatment according to the Investigator's judgment.

Exclusion Criteria:

• Chemotherapy or small molecule antineoplastic agent given within 21 days or <5 half-lives, whichever is shorter, prior to first dose of study treatment.

• History or current condition (such as transfusion-dependent anemia or thrombocytopenia), or laboratory abnormality that might confound the study results, or interfere with the patient's participation for the full duration of the study treatment.

• Patients who are pregnant or breastfeeding.

• Known sensitivity to any of the ingredients of RP-6306, carboplatin and paclitaxel. Patients are eligible if pre-medications with steroids previously controlled sensitivity and patient was able to receive treatment.

• Patients who are unable to swallow oral medications.

• Prior treatment with a WEE1 inhibitor or PKMYT1 inhibitor.

• Life-threatening illness, medical condition, active uncontrolled infection, or organ system dysfunction (such as ascites, coagulopathy, or encephalopathy), or other reasons which, in the Investigator's opinion, could compromise the participating patient's safety, or interfere with or compromise the integrity of the study outcomes.

• Major surgery within 4 weeks prior to first dose of study treatment.

• Uncontrolled, symptomatic brain metastases. Patients with previously treated brain metastases may participate provided the metastases are stable, they have no evidence of new or enlarged brain metastases, and they are clinically stable and off steroids for at least 7 days prior to study treatment.

• Uncontrolled hypertension despite adequate treatment prior to first dose of study treatment.

• Gastrointestinal disorders that may significantly interfere with absorption of the study medication by Investigator's assessment.

• Active, uncontrolled bacterial, fungal, or viral infection, including hepatitis B virus, hepatitis C virus, known human immunodeficiency virus (HIV), or AIDS-related illness. In equivocal cases, patients whose viral load is negative may be eligible. HIV seropositive patients who are healthy and low risk for AIDS-related outcomes could be considered eligible.

• Moderate or severe hepatic impairment (ie, Child-Pugh Class B or C) at the time of registration.

• Any of the following cardiac diseases currently or within the last 6 months as defined by New York Heart Association (NYHA) =Class 2:

1. Unstable angina pectoris

2. Congestive heart failure

3. Acute myocardial infarction

4. Conduction abnormality not controlled with pacemaker or medication

5. Significant ventricular or supraventricular arrhythmias (patients with chronic rate-controlled atrial fibrillation in the absence of other cardiac abnormalities are eligible)

6. Clinically relevant electrolyte abnormalities

• Current treatment with medications that are well-known to prolong the QT interval.

• Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol and/or follow-up procedures outlined in the protocol.

• Patients who are receiving strong CYP3A inhibitors or inducers within 14 days prior to first dose of study treatment, investigational therapy or anticancer agents, or antiviral therapies that are sensitive CYP3A substrates.

Related Conditions & MeSH terms

• Advanced Cancer
• Metastatic Cancer
• Recurrence
• Recurrent Ovarian Cancer
• Uterine Neoplasms

Intervention

Drug:
• RP-6306
RP-6306 is a selective inhibitor of PKMYT1 kinase. RP-6306 is an investigational agent.
• Carboplatin
Carboplatin is an antineoplastic agent.
• Paclitaxel
Paclitaxel is an antineoplastic agent.

Locations

Country	Name	City	State
Canada	Princess Margaret Cancer Centre	Toronto	Ontario

Sponsors (1)

Lead Sponsor	Collaborator
University Health Network, Toronto

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Frequency of dose-limiting toxicities (DLTs) at Dose Level 1		21 days
Primary	Frequency of dose-limiting toxicities (DLTs) at Dose Level 2		21 days
Primary	Frequency of dose-limiting toxicities (DLTs) at Dose Level -1		21 days
Primary	Frequency of dose-limiting toxicities (DLTs) at Dose Level -2		21 days
Secondary	Incidence of treatment-emergent adverse events (TEAEs)		4 years
Secondary	Progression-free survival	Time from the first day of study treatment to disease progression.	6 months
Secondary	Objective response rate	Proportion of patients with confirmed complete response (CR) or partial response (PR)	4 years
Secondary	Disease Control Rate	Proportion of patients with a confirmed best response of CR or PR, or stable disease	At least 4 months after first dose of study treatment
Secondary	Duration of Response	Time interval between the date of the earliest qualifying response (CR or PR) and the date of disease progression or death for any cause, whichever occurs earlier	4 years
Secondary	Average change in tumour size		4 years
Secondary	Plasma concentrations of RP-6306		Cmax, time to Tmax